Olfr628 inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of the Olfr628 protein, a member of the olfactory receptor family within the G-protein-coupled receptor (GPCR) superfamily. Olfactory receptors like Olfr628 are crucial components of the olfactory system, responsible for detecting and transducing odorant molecules into neural signals that lead to the perception of smell. These receptors are embedded in the membranes of olfactory sensory neurons located in the nasal epithelium. When an odorant molecule binds to Olfr628, the receptor undergoes a conformational change that activates an intracellular signaling cascade involving G-proteins. This cascade ultimately generates an electrical signal that is transmitted to the brain, where it is interpreted as a specific odor. Inhibitors of Olfr628 are small molecules that bind to the receptor's odorant-binding site or other critical regions, blocking the receptor's interaction with odorant molecules and preventing the initiation of the olfactory signal transduction process.
The development of Olfr628 inhibitors requires a detailed understanding of the receptor's structural biology and the molecular interactions that facilitate its function. Researchers often use high-throughput screening techniques to identify initial lead compounds that can effectively inhibit Olfr628. These lead compounds are then optimized through structure-activity relationship (SAR) studies, where modifications to their chemical structures are made to enhance binding affinity, specificity, and stability within the receptor's binding pocket. The chemical architecture of Olfr628 inhibitors is diverse, typically incorporating functional groups that enable strong interactions with the receptor, such as hydrogen bonds, hydrophobic interactions, and van der Waals forces. To gain deeper insights into how these inhibitors interact with Olfr628, advanced structural biology techniques like X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy are employed. These techniques allow researchers to visualize the binding interactions at an atomic level, providing critical information that guides the refinement and optimization of these inhibitors. Achieving high selectivity is a key objective in the development of Olfr628 inhibitors, ensuring that these compounds specifically target Olfr628 without affecting other olfactory receptors or GPCRs with similar structural features. This selectivity is essential for enabling precise modulation of Olfr628 activity, allowing researchers to investigate its specific role in olfactory perception and to deepen their understanding of the molecular mechanisms underlying the sense of smell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Temozolomide | 85622-93-1 | sc-203292 sc-203292A | 25 mg 100 mg | $89.00 $250.00 | 32 | |
Alkylating agent, might influence DNA repair pathways, potentially affecting Olfr628 indirectly. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor, can modulate cell growth and survival pathways possibly relevant to Olfr628. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
EGFR inhibitor, potentially disrupts growth factor signaling pathways involving Olfr628. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
EGFR inhibitor, might affect signaling pathways related to Olfr628's activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor, could impact protein degradation pathways that involve Olfr628. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Kinase inhibitor, may influence multiple signaling pathways possibly linked to Olfr628. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Tyrosine kinase inhibitor, could modulate signaling pathways relevant to Olfr628. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $193.00 $510.00 $1072.00 | 4 | |
Multi-kinase inhibitor, might affect angiogenesis and other signaling pathways involving Olfr628. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Src family kinase inhibitor, potentially modulates signaling pathways where Olfr628 is involved. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
BCR-ABL inhibitor, can influence signaling pathways related to Olfr628's function. | ||||||